Trametinib, which is an MEK inhibitor, and dabrafenib, which is a BRAF inhibitor, are used to treat solid tumors, lymphomas, or multiple myeloma with BRAF V600E driver mutation [65]. Here, MAP2K7 is linked to plasma cell myeloma.